Trump Medicaid drug plan may hand Novo Nordisk financial windfall

The Trump administration's plan to lower Medicaid drug costs may inadvertently benefit Novo Nordisk, potentially through an exception in the pricing framework. The specific mechanism is unclear, but the implication is that a policy intended to reduce costs could create a financial advantage for the company. This matters because it could affect drug pricing dynamics and public health spending.